Dosimetry and treatment efficiency of SBRT using TaiChiB radiotherapy system for two-lung lesions with one overlapping organs at risk
Journal of X-Ray Science and Technology: Clinical Applications of Diagnosis and Therapeutics · 2024
DOI: 10.3233/xst-230176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of X-Ray Science and Technology: Clinical Applications of Diagnosis and Therapeutics, 2024. Verfasst von Yanhua Duan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Modern Physics, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Radiosurgery, Lung Neoplasms, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Purpose
This study aims to assess the dosimetry and treatment efficiency of TaiChiB-based Stereotactic Body Radiotherapy (SBRT) plans applying to treat two-lung lesions with one overlapping organs at risk.
Methods
For four retrospective patients diagnosed with two-lung lesions each patient, four treatment plans were designed including Plan Edge , TaiChiB linac-based, RGS-based, and a linac-RGS hybrid (Plan TCLinac , Plan TCRGS , and Plan TCHybrid ). Dosimetric metrics and beam-on time were employed to evaluate and compare the TaiChiB-based plans against Plan Edge .
Results
For Conformity Index (CI), Plan TCRGS outperformed all other plans with an average CI of 1.06, as opposed to Plan Edge′ s 1.33. Similarly, for R 50 % , Plan TCRGS was superior with an average R 50 % of 3.79, better than Plan Edge′ s 4.28. In terms of D 2 cm , Plan TCRGS also led with an average of 48.48%, compared to Plan Edge′ s 56.25%. For organ at risk (OAR) sparing, Plan TCRGS often displayed the lowest dosimetric values, notably for the spinal cord (D max 5.92 Gy) and lungs (D 1500cc 1.00 Gy, D 1000cc 2.61 Gy, V 10 Gy 15.14%). However, its high D max values for the heart and great vessels sometimes exceeded safety thresholds. Plan TCHybrid presented a balanced approach, showing doses comparable to or better than Plan Edge without crossing safety limits. In terms of beam-on time, Plan TCLinac emerged as the most efficient treatment option in three out of four cases, followed closely by Plan Edge in one case. Plan TCRGS , despite its dosimetric advantages, was the least efficient, recording notably longer beam-on times, with a peak at 33.28 minutes in Case 2.
Conclusion
For patients with two-lung lesions treated by SBRT whose one lesion overlaps with OARs, the Plan TCHybrid delivered by TaiChiB digital radiotherapy system can be recommended as a clinical option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Modern Physics, Fudan University, Shanghai, China.
- Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Duan, Y., Feng, A., Wang, H., Chen, H., Gu, H., Shao, Y., Huang, Y., Shen, Z., Kong, Q., & Xu, Z. (2024). Dosimetry and treatment efficiency of SBRT using TaiChiB radiotherapy system for two-lung lesions with one overlapping organs at risk. Journal of X-Ray Science and Technology: Clinical Applications of Diagnosis and Therapeutics. https://doi.org/10.3233/xst-230176
Vancouver
Duan Y, Feng A, Wang H, Chen H, Gu H, Shao Y, et al. Dosimetry and treatment efficiency of SBRT using TaiChiB radiotherapy system for two-lung lesions with one overlapping organs at risk. Journal of X-Ray Science and Technology: Clinical Applications of Diagnosis and Therapeutics. 2024. doi:10.3233/xst-230176
BibTeX
@article{Duan2024,
author = {Duan, Yanhua and Feng, Aihui and Wang, Hao and Chen, Hua and Gu, Hengle and Shao, Yan and Huang, Ying and Shen, Zhenjiong and Kong, Qing and Xu, Zhiyong},
title = {Dosimetry and treatment efficiency of SBRT using TaiChiB radiotherapy system for two-lung lesions with one overlapping organs at risk},
journal = {Journal of X-Ray Science and Technology: Clinical Applications of Diagnosis and Therapeutics},
year = {2024},
doi = {10.3233/xst-230176}
}
EUVIMED